What does this research mean for the field?

A dual-targeting antibody strategy that binds both blood-brain barrier transcytosis receptors and intra-brain anchoring proteins achieves efficient brain delivery and sustained retention of therapeutic molecules. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To develop and evaluate a dual-targeting antibody delivery platform that combines blood-brain barrier transport with binding to intra-brain targets to achieve sustained retention in the brain parenchyma.

August 30, 2026mAbsOpen Access

Efficient brain delivery and sustained retention of antibodies via dual targeting of blood–brain barrier and intra-brain proteins

View Full Paper

Ask AI

Bookmark

Authors

YNYuki NoguchiUniversity Health Network NHNaoka HironiwaChugai Pharma (United States)KSKazuki SatoChugai Pharma (United States)

Discussion

Member takes

Implication

Preclinical study reveals sustained antibody retention in mouse brain, highlighting dual-targeting delivery for central nervous system therapies.

Key Points

To develop and evaluate a dual-targeting antibody delivery platform that combines blood-brain barrier transport with binding to intra-brain targets to achieve sustained retention in the brain parenchyma.
Engineered bispecific antibodies binding both blood-brain barrier transcytosis receptors (such as transferrin receptor) and intra-brain proteins (such as myelin oligodendrocyte glycoprotein).
Evaluated pharmacokinetic profiles, immunohistochemistry, and whole-brain 3D imaging in mice over a 4-month period.
Delivered neprilysin, an amyloid-beta-degrading enzyme, via this platform to measure pharmacodynamic effects in the brain.
The bispecific anti-MOG/TfR antibody achieved higher peak brain concentrations and maintained superior exposure across four months compared to monospecific anti-MOG or anti-TfR antibodies.
Whole-brain three-dimensional imaging confirmed antibody penetration across the blood-brain barrier into the entire brain parenchyma with sustained tissue retention.
Conjugation with neprilysin significantly enhanced central nervous system exposure and the functional degradation of amyloid beta.

Cite This Study

Noguchi et al. (2026) studied this question.

synapsesocial.com/papers/6a93f0b06c1a8fb52e79d102 https://doi.org/10.1080/19420862.2026.2724587

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study reveals sustained antibody retention in mouse brain, highlighting dual-targeting delivery for central nervous system therapies.

Efficient brain delivery and sustained retention of antibodies via dual targeting of blood–brain barrier and intra-brain proteins

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficient brain delivery and sustained retention of antibodies via dual targeting of blood–brain barrier and intra-brain proteins

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider